SCHEMBL272183

SCHEMBL272183

[CH2]CNC(=O)OCc1ccccc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.65
SMN1; SMN2 Q16637 1/20 0.65
HTT P42858 1/20 0.61
TGM2 P21980 1/20 0.57
CA12 O43570 2/20 0.54
CA1 P00915 2/20 0.54
CA2 P00918 2/20 0.54
CA9 Q16790 2/20 0.54
ALDH1A1 P00352 3/20 0.53
NPC1 O15118 1/20 0.53
RAB9A P51151 1/20 0.53
POLB P06746 1/20 0.53
L3MBTL1 Q9Y468 3/20 0.52
PLAU P00749 1/20 0.52
KEAP1 Q14145 1/20 0.52
NFE2L2 Q16236 1/20 0.52
MAPK1 P28482 1/20 0.52
SLC6A2 P23975 1/20 0.52
SLC6A3 Q01959 1/20 0.52
KMT2A Q03164 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1415897 0.86 LMNA (0.71) LMNASMN1; SMN2HTTTGM2CA12
SCHEMBL13055383 0.85 LMNA (0.80) LMNASMN1; SMN2HTTTGM2CA12
Benzyl Benzylcarbamate SCHEMBL1136818 0.83 PLAU (0.70) LMNASMN1; SMN2HTTTGM2CA12
SCHEMBL250620 0.83 LMNA (0.67) LMNASMN1; SMN2HTTTGM2CA12
SCHEMBL8197237 0.83 LMNA (0.67) LMNASMN1; SMN2HTTTGM2CA12
SCHEMBL646561 0.83 HTT (0.72) LMNASMN1; SMN2HTTTGM2L3MBTL1
SCHEMBL19477991 0.82 LMNA (0.66) LMNASMN1; SMN2HTTTGM2CA12
SCHEMBL4910834 0.82 MGLL (0.52) LMNASMN1; SMN2ALDH1A1NPC1RAB9A
SCHEMBL2295789 0.82 CA12 (0.66) LMNASMN1; SMN2HTTCA12CA1
SCHEMBL3728729 0.82 HTT (0.70) LMNASMN1; SMN2HTTTGM2L3MBTL1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 460 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-11998621-B2 Transparent, fracture-tough polymerization resins for the production of dental shaped bodies IVOCLAR VIVADENT AG (LI) 2024-06-04 US claimed
CN-115300400-A Transparent, fracture-tough polymeric resins for the production of dental molded bodies 义获嘉伟瓦登特公司 2022-11-08 CN claimed
EP-3050883-B1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVES AND INTERMEDIATES MEIJI SEIKA PHARMA CO LTD (JP) 2020-04-22 EP claimed
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof MEIJI SEIKA PHARMA CO., LTD. (JP) 2018-06-19 US claimed
CN-105555787-B Process for preparation of diazabicyclooctane derivatives and intermediates therefor 明治制果药业株式会社 2017-08-08 CN claimed
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF MEIJI SEIKA PHARMA CO., LTD. (JP) 2016-09-15 US claimed
EP-3050883-A1 PRODUCTION METHOD FOR DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIARY BODY THEREOF Meiji Seika Pharma Co., Ltd. (JP) 2016-08-03 EP claimed
CN-105555787-A Process for preparation of diazabicyclooctane derivatives and intermediates therefor MEIJI SEIKA PHARMA CO LT 2016-05-04 CN claimed
JP-4664597-B2 2011-04-06 JP claimed
EP-1511734-B1 COMPOUNDS, COMPOSITIONS, AND METHODS CYTOKINETICS INC (US) 2010-06-23 EP claimed
WO-1993023402-A1 3-AZETIDINYLTHIO-CARBAPENEME DERIVATIVES, THEIR PREPARATION AND USE AS ANTIMICROBIAL AGENTS FUJISAWA PHARMACEUTICAL CO., LTD. (JP) 1993-11-25 WO claimed
EP-0329013-A2 Renin-inhibiting amino acid derivatives HOECHST AKTIENGESELLSCHAFT (DE) 1989-08-23 EP claimed
EP-0047079-B1 NONAPEPTIDES AFFECTING GONADAL FUNCTION THE SALK INSTITUTE FOR BIOLOGICAL STUDIES (US) 1984-02-22 EP claimed
EP-0040494-B1 CARBAPENAMS AND CARBAPEN-2-EMS AND PROCESS THEREFOR PFIZER INC. (US) 1984-02-15 EP claimed
US-4429128-A CARBAPENICILLINS, THIENAMYCINS, BACTERICIDES PFIZER INC. (US) 1984-01-31 US claimed
EP-0005348-B1 CARBAPENEM DERIVATIVES, A PROCESS FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM BEECHAM GROUP PLC (GB) 1982-09-22 EP claimed
US-4348264-A Photocatalyzed process for producing carbapenams and carbapen-2-ems PFIZER INC. (US) 1982-09-07 US claimed
EP-0040494-A1 Carbapenams and carbapen-2-ems and process therefor PFIZER INC. (US) 1981-11-25 EP claimed
US-4278686-A ANTIBIOTICS BEECHAM GROUP LIMITED (GB) 1981-07-14 US claimed
EP-0005348-A1 Carbapenem derivatives, a process for their preparation and pharmaceutical compositions containing them BEECHAM GROUP PLC (GB) 1979-11-14 EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11998621-B2 Transparent, fracture-tough polymerization resins for the production of dental shaped bodies MMAB, VCL, BOLA2; BOLA2B LMNA 1795/4885SMN1; SMN2 3002/4885HTT 847/4885
US-20160264573-A1 PROCESS FOR PRODUCING DIAZABICYCLOOCTANE DERIVATIVE AND INTERMEDIATE THEREOF CLCN2, ODC1, KCNN4 LMNA 921/4885SMN1; SMN2 4784/4885HTT 2820/4885
US-10000491-B2 Process for producing diazabicyclooctane derivative and intermediate thereof CLCN2, ODC1, KCNN4 LMNA 921/4885SMN1; SMN2 4784/4885HTT 2820/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.